Kadoaki Ohashi

Okayama University Hospital

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Collaborators (4)

Terufumi Kato

Chief Physician

Kanagawa Cancer Center

Naoki Furuya

Ohio State University

UNITED STATES

Nahoko Tomonobu

Assistant Professor

Okayama University

Katsuyuki Kiura

Okayama University Hospital

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kadoaki Ohashi

Research Interests

Explore related searches

Contact this professor

Articles (11)

Collaborators (4)

Terufumi Kato

Naoki Furuya

Nahoko Tomonobu

Katsuyuki Kiura

Make your next move.

Kadoaki Ohashi

Research Interests

Explore related searches

Contact this professor

Articles (11)

Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia

PD-1 blockade augments CD8+ T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer

CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer

Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan: A Case Report.

Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.

Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression.

SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve <i>ALK-, ROS1-</i>, or <i>EGFR</i>-altered Non-small Cell Lung Cancer.

A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.

A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1<sup>+</sup> lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations.

Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease.

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.

Collaborators (4)

Terufumi Kato

Naoki Furuya

Nahoko Tomonobu

Katsuyuki Kiura

Make your next move.